Literature DB >> 11068314

Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy.

J Nakashima1, C Ozu, T Nishiyama, M Oya, T Ohigashi, H Asakura, M Tachibana, M Murai.   

Abstract

OBJECTIVES: To assess the prognostic significance of alkaline phosphatase (ALP) flare in 114 patients with metastatic prostate cancer treated with endocrine therapy.
METHODS: ALP flare was defined as a transient increase of the serum ALP level to 120% or more of the pretreatment value after the initiation of endocrine therapy, followed by a subsequent decrease.
RESULTS: Univariate analysis demonstrated that patients with poorly differentiated adenocarcinoma, an extent of disease of 2 or greater, a serum ALP level above twice the upper limit of normal, a serum prostate-specific antigen level greater than 100 ng/mL, an ALP flare, and a hemoglobin level of 12 g/dL or less had a significantly lower survival rate than their respective counterparts. Multivariate Cox's proportional hazards model analysis demonstrated that tumor histologic features and ALP flare were significant prognostic indicators for survival.
CONCLUSIONS: The results of the present study suggest that the tumor histologic features and the ALP flare are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with endocrine therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11068314     DOI: 10.1016/s0090-4295(00)00755-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis.

Authors:  Kyung Seok Han; Sung Joon Hong
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-24       Impact factor: 4.553

2.  Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer.

Authors:  Angelo Castello; H A Macapinlac; E Lopci; E B Santos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-21       Impact factor: 9.236

3.  Prognostic value of serum alkaline phosphatase in the survival of prostate cancer: evidence from a meta-analysis.

Authors:  Dongyang Li; Hang Lv; Xuanyu Hao; Bin Hu; Yongsheng Song
Journal:  Cancer Manag Res       Date:  2018-08-30       Impact factor: 3.989

4.  Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer.

Authors:  Akihiro Yano; Makoto Kagawa; Hideki Takeshita; Yohei Okada; Makoto Morozumi; Satoru Kawakami
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

5.  Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.

Authors:  Keiichiro Mori; Florian Janisch; Mehdi Kardoust Parizi; Hadi Mostafaei; Ivan Lysenko; Dmitry V Enikeev; Shoji Kimura; Shin Egawa; Shahrokh F Shariat
Journal:  Int J Clin Oncol       Date:  2019-11-25       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.